乙型脑炎及其疫苗概况

摘要/Abstract

摘要： 乙型脑炎是由乙型脑炎病毒引起的，在自然界中主要以鸟、猪为宿主，经蚊为主的虫媒传播的一种人兽共患传染病。该病主要流行于亚洲地区及环西太平洋地区，已成为人类脑炎疾病最主要的病因之一，严重威胁着人类健康，并影响畜牧业特别是养猪业的发展。WHO 公布数据显示，每年大约有50 000 例乙型脑炎患者，造成至少10 000 例死亡及15 000 例神精后遗症患者，但至今仍无有效的治疗措施，接种疫苗依然是预防JEV 感染的最佳途径。介绍JE 的流行病学特点，乙型脑炎的发病情况，重点综述国内外市场上使用的JE 疫苗情况及其最新研究进程，希望对我国JE 疫苗的使用及研发提供有益参考。

关键词: 乙型脑炎 , 疫苗 , IC51 , IMOJEV? , SA14-14-2

Abstract: Japanese encephalitis, an insect-borne zoonotic infectious disease, is caused by Japanese encephalitis virus(JEV)and themost important hosts of which in nature is birds and pigs. This disease occurs mainly in Asia and Central-West Pacific regions, and has becomeone of the most serious encephalitis diseases which threats to human health and affects the development of animal husbandry particular in pigfarming industry. Published date from WHO showed that an estimated 50 000 cases occur in this region, resulting in at least 10 000 deaths and15 000 cases of neuropsychiatric sequelae. However, there is no effective antiviral therapeutic is available to treat JE, and vaccination is the mosteffective method to prevent JEV infection. This paper introduces the epidemiological characteristics and enphalitis disease, focuses on reviewof JE vaccines in the market and the latest research process. The present paper would provide useful reference for use and development of JEvaccines in China.

Key words: Japanese encephalitis , Vaccine IC51 , IMOJEV , SA14-14-2

沈强, 史子学, 魏建超, 马志永. 乙型脑炎及其疫苗概况[J]. 生物技术通报, 2013, 0(1): 56-62.

Shen QiangShi Zixue, Wei Jianchao, Ma Zhiyong. Japanese Encephalitis and Its Vaccines[J]. Biotechnology Bulletin, 2013, 0(1): 56-62.

参考文献

[1] Solomon T, Ni H, Beasley DWC, et al. Origin and evolution ofJapanese encephalitis virus in southeast Asia[J]. J Virol, 2003,77（5）：3091-3098.
[2] Zheng YY, Li MH, Wang HY, et al. Japanese encephalitis and Japaneseencephalitis virus in maindland China[J]. Medical Virology,2012, 22（5）：301-322.
[3] Mitamura T, Kitaoka M, Watanabe M, et al. Study on Japaneseencephalitis virus. Animal experiments and mosquito transmissionexperiments[J]. Kansai Iji, 1936, 1 ：260-261.
[4] Mitamura T, Kitaoka M, Mori K, et al. Isolation of the virusof Japanese epidemic encephalitis from mosquitoes caught innature[J]. Tokyo Iji Shinshi, 1938, 62 ：820-824.
[5] Andrew F. Van den Hurk, Scott A. Ritchie. Ecology and geographicalexpansion of Japanese encephalitis virus[J]. Annu Rev Entomol,2009, 54 ：17-35.
[6] Erlanger TE, Weiss S, Keiser J, et al. Past, present, and future ofJapanese encephalitis[J]. Emerging Infectious Diseases, 2009,15 ：1-7.
[7] Campbell GL, Hills SL, Fischer M, et al. Estimated global incidenceof Japanese encephalitis ：a systematic review[J]. Bulletin of theWorld Health Organization, 2011, 89 ：766-774.
[8] Solomon T, Vaughn DW. Pathogenesis and clinical features ofJapanese encephalitis and West Nile virus infections[J]. Curr TopMicrobiol Immunol, 2002, 267 ：171-194.
[9] Parida M, Dash PK, Tripathi NK, et al. Japanese encephalitisoutbreak, India, 2005[J]. Emerg Infect Dis, 2006, 12 ：1427-1430.
[10] Halstead SB, Jacobson J. Japanese Encephalitis Vaccines
[R]. IIPlotkin SA, Orenstein WA, Offit P, editors, Vaccines. Fourth edition：Philadelphia. Saunders Elsevier, 2008 ：311-352.
[11] Solomon T, Dung NM, Wills B, et al. Interferon alfa-2a in Japaneseencephalitis ：a randomised double-blind placebo-controlledtrial[J]. Lancet, 2003, 361（9360）：821-826.
[12] Herwig K, Maria PK, Katrin DK. IC51 Japanese encephalitisvaccine[J]. Expert Opin Biol Ther, 2009, 9（7）：921-931.
[13] Schioler KL, Samuel M, Wai KL. Vaccines for preventing Japaneseencephalitis[J]. Cocbrance Datebase Syst Rev, 2007, 3 ：1-44.
[14] Halstead SB, Thomas SJ. New Japanese enphalitis vaccines ：alternatives to production in mouse brain[J]. Expert RevVaccine, 2011, 10（3）：355-364.
[15] Poland J, Cropp C, Craven R, Monath T. Evaluation of the potencyand safety of in activated Japanese encephalitis vaccine in USinhabitants[J]. J Infect Dis, 1990, 161 ：878-882.
[16] Centers for disease control and prevention. Inactivated Japanese encephalitisvirus vaccine. Recommendations of the Advisory Committeeon Immunization Practices（ACIP）
[R]. MMWR MorbMortal, Wkly Rep, 1993, 42 ：1-15.
[17] Ruff TA, Eisen D, Fuller A, et al. Adverse reactions to Japaneseencephalitis vaccine[J]. Lancet, 1991, 338（8771）：881-882.
[18] Nothdurft HD, Jelinek T, Marschang A, et al. Adverse reactions toJapanese encephalitis vaccine in travellers[J]. J Infect, 1997, 32（2）：119-122.
[19] 白登云, 陈伯权, 俞永新, 等. 虫媒病毒与虫媒病毒病[J].昆明：云南科技出版社, 1994 ：65-78.
[20] 卢锦汉, 章以浩, 赵恺, 等. 医学生物制品学[M]. 北京：人民卫生出版社, 1995 ：528-539.
[21] Jia LL, Wang ZW, Yu YX. Protection of SA14-14-2 live attenuatedJapanese encephalitis vaccine against the wild-type JE viruses[J].Chin Med J, 2003, 116（6）：941-943.
[22] 马文信, 俞永新, 王寿贵, 等. 流行性乙型脑炎活疫苗大面积人体接种的安全性和血清学效果观察[J]. 中国生物制品学杂志, 1993, 6（4）：188-191.
[23] 贾丽丽, 郑铮, 俞永新, 等. 流行性乙型脑炎流行区内儿童接种乙脑减毒活疫苗后的免疫应答[J]. 中国人畜共患病杂志,1995, 11（6）：343-344.
[24] Tomas Jelinek. Ixiaro? ：a new vaccine against Japanese encephalitis[J]. Vaccine, 2009, 8（11）：1501-1511.
[25] Umenai T, Krzysko R, Bektimirov A, Assaad A. Japanese encephalitis：current worlwide staus[J]. Bull World Health Organ, 1985,63 ：623-631.
[26] Lyons A, Kanesa-thasan N, Kuschner RA, et al. A phase 2 study ofa purified, inactivated virus vaccine to prevent Japanese encephalitis[J]. Vaccine, 2007, 25（17）：3445-3453.
[27] Srivastava AK, Putnak JR, Lee SH, et al. A purified inactivatedJapanese encephalitis virus vaccine made in vero cells[J]. Vac生物技术通报 Biotechnology Bulletin 2013年第1期62cine, 2001, 19（31）：4557-4565.
[28] Ni H, Burns NJ, Chang GJ, et al. Comparsion of nucleotide andduduced amino acid sequence of the 5’non-coding region andstructural protein genes of the wild-type Japanese encephalitis virusstrain SA14 and its attenuated vaccine derivatives[J]. J GenVirol, 1994, 75（6）：1505-1510.
[29] Tauber E, Kollaritsch H, Korinek M, et al. Safety and immunogenicityof a vero-cell-derived, inactivated Japanese encephalitis vaccine：a non-inferiority, Phase III, randomized controlled trial[J].Lancet, 2007, 370（9602）：1847-1853.
[30] Kaltenb?ck A, Dubischar-Kastner K, Eder G, et al. Safety and immunogenicityof concomitant vaccination with the cell-culture basedJapanese Encephalitis vaccine IC51 and the hepatitis A vaccineHAVRIV? 1440 in healthy subjects ：a single-blind, randomized,controlled Phase 3 study[J]. Vaccine, 2009, 27（33）：4483-4489.
[31] Kaltenb?ck A, Dubischar-Kastner K, Schuller E, et al. Immunogenicityand safety of IXIARO?（IC51）in a Phase II study in healthyIndian children between 1 and 3 years of age[J]. Vaccine, 2010,28 ：834-839.
[32] 杨臻峥. 乙型脑炎疫苗IC51[J]. 药学进展, 2010, 34（5）：234-236.
[33] Fischer U, Lindsey N, Staples JE, et al. Japanese Encephalitis Vaccines.Recommendations of the Advisory Committee on ImmunizationPractices（ACIP）
[R]. MMWR Morb Mortal Wkly Rep,2010, 59 ：1-26.
[34] Appaiahgari MB, Vrati S. IMOJEV? ：a Yellow fever virus-badednovel Japanese enphalitis vaccine[J]. Vaccine, 2010, 9（12）：1371-1384.
[35] Pugachev KV, Guirakhoo F, Monath TP. New developments inflavivirus vaccines with special attention to yellow fever[J]. CurrOpin Infect Dis, 2005, 8 ：387-394.
[36] Guy B, Guirakhoo F, Barban V, et al. Preclinical and clinical developmentof YFV 17D-based chimeric vaccines against dengue, WestNile and Japanese encephalitis viruses[J]. Vaccine. 2010, 28 ：632-649.
[37] Guirakhoo F, Zhang ZX, Chambers TJ, et al. Immunogenicity, geneticstability, and protective efficacy of a recombinant, chimeric yellowfever-Japanese encephalitis virus（ChimeriVax-JE）as a live,attenuated vaccine candidate against Japanese encephalitis[J].Virology, 1999, 257 ：363-372.
[38] Lobigs M, Larena M, Alsharifi M, et al. Live chimeric and inactivatedJapanese encephalitis virus vaccines differ in their cross-protectivevalues against Murray Valley encephalitis virus[J]. J Virol,2009, 83 ：2436-2445.
[39] Chambers TJ, Nestorowiez A, Mason PW, et al. Yellow fever/ Japaneseenphalitis chimeric viruses ：construction and biologieal properties[J]. Journal of Virology, 1999, 73（4）：3095-3310.